title: Evidence of HLA class II association with antibody response against the malaria vaccine SPF66 in a naturally exposed population.
abstract: The antibody response against the malaria vaccine SPf66 and against circumsporozoite (CS) protein has been tested in immune adults from a malaria endemic area in Papua New Guinea. All individuals were genotyped for the HLA class II DQB1 and DRB1 loci, and the humoral response was analyzed with respect to the identified class II alleles. At each locus, only three alleles were frequent, namely DRB1*11, *15, and *16, and DQB1*0301, *0502, and *0601. Antibodies against SPf66 and CS protein were found in 84% and 79% of the individuals, respectively. A strong negative association was detected between the humoral response against SPf66 and DRB1*15 and DQB1*0601. A positive association of the response was observed with DRB1*11 and DQB1*0301. After analysis with a multiple regression model in which all alleles were included simultaneously, only DRB1*15 remained significantly associated with low antibody responses. This suggests that nonresponders may be expected after immunization with SPf66 in certain populations.
authors.affiliation: Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea.
authors.forename: H P
authors.initials: HP
authors.lastname: Beck
authors.forename: I
authors.initials: I
authors.lastname: Felger
authors.forename: M
authors.initials: M
authors.lastname: Barker
authors.forename: T
authors.initials: T
authors.lastname: Bugawan
authors.forename: B
authors.initials: B
authors.lastname: Genton
authors.forename: N
authors.initials: N
authors.lastname: Alexander
authors.forename: E
authors.initials: E
authors.lastname: Jazwinska
authors.forename: H
authors.initials: H
authors.lastname: Erlich
authors.forename: M
authors.initials: M
authors.lastname: Alpers
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis*; D001483:Base Sequence; D017931:DNA Primers; D005802:Genes, MHC Class II; D005838:Genotype; D006683:HLA-DQ Antigens / Q000235:genetics; D059866:HLA-DQ beta-Chains; D006684:HLA-DR Antigens / Q000235:genetics; D059811:HLA-DRB1 Chains; D006801:Humans; D017780:Malaria Vaccines / Q000276:immunology*; D016778:Malaria, Falciparum / Q000276:immunology / Q000517:prevention & control; D008875:Middle Aged; D008969:Molecular Sequence Data; D010963:Plasmodium falciparum / Q000276:immunology*; D011110:Polymorphism, Genetic; D015800:Protozoan Proteins / Q000276:immunology*; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic / Q000276:immunology*
chemical_list: D000913:Antibodies, Protozoan; D017931:DNA Primers; D006683:HLA-DQ Antigens; D059866:HLA-DQ beta-Chains; C069051:HLA-DQB1 antigen; D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; D017780:Malaria Vaccines; D015800:Protozoan Proteins; D011994:Recombinant Proteins; C066269:SPf66 protein, Plasmodium; D014614:Vaccines, Synthetic; C041595:circumsporozoite protein, Protozoan